Herpes simplex virus glycoprotein D variants
US5814486A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 7, 1997 |
| Grant date | Sep 29, 1998 |
| Priority date | — |
| Expiry date | May 7, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/224
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When exposed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t)…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.